T Helper 17 [TH17] cells and the production of signature TH17 cytokines interleukin [IL]-17A and IL-17F play a critical role in the pathogenesis of several Autoimmune and Immuno-Inflammatory Diseases. The therapeutic efficacy of targeting IL-17 to prevent disease onset and to delay disease progression has been established in experimental animal disease models and in recent clinical Proof of Concept trials in several autoimmune diseases. These implicate TH17 cells as critical novel targets of future immunomodulatory therapeutic development for these disorders with high unmet medical needs. Retinoic acid receptor-related Orphan Receptor [ROR] gamma (t) is the master regulator of human TH17 cellular differentiation, function and cytokine production. Using rational SBDD, Innovimmune has discovered and advanced the development of proprietary next-generation NMEs of oral small molecule ROR gamma (t) modulators of the INV-17 portfolio in target-validated autoimmune disease indications.